Breast Cancer Biosimilar Gains FDA Approval

People with HER2-positive breast cancer may eventually have a lower-cost option, with a US launch not expected until Q3 2028.

Updated on Nov. 16, 2026 in Cancer

Breast Cancer Biosimilar Gains FDA Approval

India's Biocon received US FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar of the breast cancer drug Perjeta (pertuzumab), marking its fifth oncology biosimilar cleared in the United States. The drug is approved for HER2-positive breast cancer when used with trastuzumab and chemotherapy, and a US launch is not expected until Q3 2028 under a settlement with Genentech.

Why it matters

Biosimilars can add lower-cost treatment options to HER2-positive breast cancer care, which is one of the more heavily treated subtypes, so approvals like this bear on how accessible established therapies become over time. The timing of the launch is set by a global settlement and licence agreement with Genentech rather than by approval alone, which is why a cleared product may still be months or years from reaching patients.

This is a regulatory approval of a biosimilar, which must show similarity to the reference product Perjeta rather than independent clinical superiority. The source does not report trial sizes, effect measures or study duration for Pebrilzo, so the strength of the clinical evidence cannot be assessed from this report.

The players

Biocon Limited

An Indian biopharmaceutical company that develops biosimilar versions of biologic medicines, with an oncology portfolio that includes Ogivri, Jobevne, Fulphila and Aukelso.

Genentech

A member of the Roche group and the developer of Perjeta (pertuzumab), the reference product for Pebrilzo, with a long-standing focus on oncology and immunology therapies.

The details

Pebrilzo is a monoclonal antibody that blocks HER2 receptors on cancer cells, the proteins that drive the growth of HER2-positive breast tumours. It is used in combination with trastuzumab and chemotherapy rather than alone. Biosimilars are designed to match an approved reference biologic, so the approval reflects regulatory judgment that Pebrilzo is highly similar to Perjeta.

Timeline

  1. September 2026: the European Medicines Agency's CHMP issued a positive opinion recommending marketing authorisation for Pebrilzo in Europe.

  2. November 16, 2026: Biocon announced US FDA approval of Pebrilzo.

  3. Q3 2028: earliest licensed US launch date for Pebrilzo under the Genentech settlement.

Health Landscape

Biosimilars of monoclonal antibodies such as pertuzumab are part of a growing set of lower-cost alternatives to originator biologics in cancer care. Pebrilzo adds a HER2-targeted option to that set, though its US availability depends on a licensing timetable rather than approval alone.

For people with HER2-positive breast cancer, biosimilars can eventually widen access to HER2-targeted treatment, but this approval does not change what is available today. Anyone undergoing treatment is best served by asking their oncologist about the options that apply to their own care.

The takeaway

A biosimilar approval signals future options rather than an immediate change in treatment. Readers with breast cancer questions about HER2-targeted therapy should raise them with their oncology team.

What happens next

Pebrilzo's European marketing authorisation will follow the CHMP positive opinion, and its earliest licensed US launch is expected in Q3 2028 under the Genentech settlement.

Further reading

For more on how targeted therapies are reshaping treatment, explore our Cancer coverage.